BROOKS

Brooks Laboratories Share Price

₹154.67 +3.03 (2%)

Stock Hit Upper Circuit

14 Jul, 2025 11:37

SIP TrendupStart SIP in BROOKS

Start SIP

Performance

  • Low
  • ₹155
  • High
  • ₹155
  • 52 Week Low
  • ₹82
  • 52 Week High
  • ₹199
  • Open Price₹155
  • Previous Close₹152
  • Volume2,636

Investment Returns

  • Over 1 Month + 23.07%
  • Over 3 Month + 16.69%
  • Over 6 Month -13.31%
  • Over 1 Year + 82.44%
SIP Lightning

Smart Investing Starts Here Start SIP with Brooks Laboratories for Steady Growth!

Invest Now

Brooks Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -36.7
  • PEG Ratio
  • -1
  • Market Cap Cr
  • 456
  • P/B Ratio
  • 7.3
  • Average True Range
  • 4.59
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.72
  • RSI
  • 64.36
  • MFI
  • 90.94

Brooks Laboratories Financials

Brooks Laboratories Technicals

EMA & SMA

Current Price
₹154.67
+ 3.03 (2%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹142.21
  • 50 Day
  • ₹137.97
  • 100 Day
  • ₹136.29
  • 200 Day
  • ₹133.93

Resistance and Support

151.64 Pivot Speed
  • R3 151.64
  • R2 151.64
  • R1 151.64
  • S1 151.64
  • S2 151.64
  • S3 151.64

What's your outlook on Brooks Laboratories?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Brooks Laboratories has an operating revenue of Rs. 100.49 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 4% needs improvement, ROE of -10% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 5% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Brooks Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-28 Audited Results
2025-02-13 Quarterly Results
2024-12-11 To consider Fund Raising & Others Inter-alia, to consider and approve 1. Proposal for Raising Funds through the issuance of securities (Equity Shares) by way of a preferential issue. 2. To approve the EGM. 3. Other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:16 @ premium of Rs. 65/-.
2024-11-09 Quarterly Results
2024-08-14 Quarterly Results

Brooks Laboratories F&O

Brooks Laboratories Shareholding Pattern

52.62%
9.9%
0%
0%
0%
32.01%
5.47%

About Brooks Laboratories

  • NSE Symbol
  • BROOKS
  • BSE Symbol
  • 533543
  • ISIN
  • INE650L01011

Similar Stocks to Brooks Laboratories

Brooks Laboratories FAQs

Brooks Laboratories share price is ₹154 As on 14 July, 2025 | 11:23

The Market Cap of Brooks Laboratories is ₹455.6 Cr As on 14 July, 2025 | 11:23

The P/E ratio of Brooks Laboratories is -36.7 As on 14 July, 2025 | 11:23

The PB ratio of Brooks Laboratories is 7.3 As on 14 July, 2025 | 11:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23